Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target
- 1 June 2005
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 14 (6) , 671-679
- https://doi.org/10.1517/13543784.14.6.671
Abstract
Although the clinical benefit of statins is well established, these agents reduce the risk of cardiovascular events by only 20 – 40%, and the residual risk for high-risk patients is considerable. The recognition of atherosclerosis as an inflammatory disease has opened the door to numerous complementary therapeutic approaches to further reduce risk and the overall burden of cardiovascular disease. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammatory marker of cardiovascular risk that is being evaluated as a potential therapeutic target. The biological function of this enzyme in atherosclerosis has been controversial but recent evidence supports its pro-atherogenic role. The enzyme is predominantly bound to low-density lipoprotein cholesterol particles in humans, and its activity produces bioactive lipid mediators that promote inflammatory processes present at every stage of atherogenesis, from atheroma initiation to plaque destabilisation and rupture. Initial clinical studies suggest t...Keywords
This publication has 69 references indexed in Scilit:
- Platelet-Activating Factor Acetylhydrolase Is Mainly Associated With Electronegative Low-Density Lipoprotein SubfractionCirculation, 2003
- Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese MiceCirculation, 2003
- Lipoprotein-Associated Phospholipase A 2 , Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Cellular Source(s) of Platelet-Activating-Factor Acetylhydrolase Activity in PlasmaBiochemical and Biophysical Research Communications, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- A Mutation in Plasma Platelet-Activating Factor Acetylhydrolase (Val 279 →Phe) is a Genetic Risk Factor for StrokeStroke, 1997
- Activation of ICAM-1 promoter by lysophosphatidylcholine: Possible involvement of protein tyrosine kinasesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1997
- Structural Differences in the Ability of Lysophospholipids to Inhibit Endothelium-Dependent Hyperpolarization by Acetylcholine in Rat Mesenteric ArteriesBiochemical and Biophysical Research Communications, 1996
- A Cytotoxic Electronegative LDL Subfraction Is Present in Human PlasmaArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- PAF-Degrading Acetylhydrolase Is Preferentially Associated With Dense LDL and VHDL-1 in Human PlasmaArteriosclerosis, Thrombosis, and Vascular Biology, 1995